1Internal Medicine Department Faculty of Medicine, Hasanuddin University, Makassar, South Sulawesi, Indonesia
2Medical Hematology and Oncology Division of Internal Medicine Department, Faculty of Medicine, Hasanuddin University, Makassar, South Sulawesi, Indonesia
*Corresponding Author: Ardan Miraz, Internal Medicine Department, Hasanuddin University, Hasanuddin University Hospital 5th Floor, Perintis Kemerdekaan Road Km. 11, Makassar 90245, South Sulawesi, Indonesia, e-mail: miraz.ardan@gmail.com
Online published on 27 March, 2020.
Treatment for non-Hodgin Lymphoma (NHL) with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) has been standard chemotherapy regimens for treatment of patients with diffuse large B cell lymphoma and follicular lymphoma. Rituximab, a chimeric monoclonal antibody against the CD20 B-cell antigen. Rituximab in combination with CHOP (RCHOP) increases better response rate without any significant increase in toxicity. The standard definition of treatment responseis based on changes in lesion dimensions with time. We conducted a comparative study to compare early response rate between CHOP andCHOP in NHL patients.
This study was using cohort prospective analysis and conducted at Wahidin Sudirohusodo Hospital from September 2018 until June 2019. The response rate was measured with the longest diameter of tumor and compared after 2 observational cycle periods of chemotherapy. Analysis to compare responserate was carried out using Independent T-test analysis.
Seventy patients enroll this study consisting of 38 subjects in CHOP group and 32 subjects in RCHOP group. Analysis to compare early responserate between CHOP and RCHOP was significant with p-value 0.001 (46.6% vs 67.0%;).
Early response rate in patient given combination targeted therapy have better response rate than patient given standard regiment chemotherapy.
Early ResponseRate, RCHOP, CHOP, non-Hodgkin Lymphoma
